BTIG analyst Kambiz Yazdi raised the firm’s price target on vTv Therapeutics (VTVT) to $49 from $40 and keeps a Buy rating on the shares. The recent comments from the FDA Commissioner on January 15, 2026 underscore that T1D is a major therapeutic priority for the Agency, which is seen as a “highly positive read-through” for the company, the analyst tells investors in a research note. vTs’ Cadisegliatin is uniquely positioned as a meaningful treatment and holds Breakthrough Therapy Designation as an oral adjunctive for T1D, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics initiated with a Buy at Roth Capital
- vTv Therapeutics: Late-Stage Cadisegliatin Data, Differentiated Mechanism, and Partnered T2D Expansion Underpin Buy Rating and $40 Target
- vTv Therapeutics initiated with a Buy at TD Cowen
- Paradigm-Shifting Potential in Type 1 Diabetes: vTv Therapeutics’ Cadisegliatin Supports Buy Rating and Significant Upside
- vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright